Lts Lohmann Therapie-systeme Ag

Lts Lohmann Therapie-systeme Gmbh

Stefan Bracht

Christoph Schmitz

Michael Horstmann

Andreas Koch

Sabine Warnus

A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value Lat a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L, with Lbeing the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the Lof their respective skin is in the range from 5&#xb0; to 100&#xb0;, especially in the range from 20&#xb0; to 90&#xb0;.

Medical active substance patch with reduced optical conspicuousness on the skin

A medical active substance patch comprising a matrix of monolayer or multilayer configuration with at least one active substance-containing layer and comprising a backing layer connected with the matrix. The active substance patch is transparent or at least translucent, and in the state of having been applied to the skin of a first person, the patch has a lightness colour value Lat a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness colour value L, Lbeing the lightness value of the region of the skin of the same person which surrounds the applied patch. The same is true of the skin of a second or any other person, provided that for all the persons mentioned Lis in the range from 5&#xb0; to 100&#xb0;, namely from 20&#xb0; to 90&#xb0;.

The invention relates to a TTS with backing layers that guarantee a high wear comfort and that facilitate application in regions of the human body that are subject to great mechanical loads, especially the large joints of the extremities. The inventive backing layers overcome the disadvantages with respect to reduced absorption of the active substance by the skin that are typically associated with such backing layers. The inventive systems are preferably used for the local of systemic administration of anti-inflammatory and pain-relieving active substances.

Occlusive transdermal therapeutic system with a non-occlusive backing layer

The invention relates to transdermal therapeutic systems which have the active ingredient nicotine and have particularly high flexibility. This flexibility decisively improves wearer comfort on the skin, since the system is readily capable of adapting to the surface of the skin and its constant movement. Surprisingly, the nicotine TTS of the invention is markedly more flexible than the conventional nicotine TTS products which are leaders in the market, although at least some of those systems are comparably thin.

Highly flexible transdermal therapeutic system having nicotine as active substance

A transdermal therapeutic system consisting of a backing layer, at least one active substance-containing matrix layer, which may at the same time possess pressure-sensitive adhesive properties, as well as a removable protective layer is characterized by a content of a neuroleptic, a content of at least one permeation enhancer as well as by a layer which is pressure-sensitive adhesive on the skin-facing side and based on polymers which are pure hydrocarbons.

Transdermal therapeutic system with a highly effective neuroleptic agent

A transdermal therapeutic system (TTS) with a content of at least one active substance from the group of the carboxyl group-containing non-steroidal antirheumatics, which has a backing layer (), an active substance-containing matrix layer () and a detachable protective layer (), is characterized by a matrix layer () based on a carboxyl group-containing polyacrylate pressure-sensitive adhesive, which matrix layer () has a content of oleic acid and potassium ions, with the constituent amount of the potassium ions being in the range of from 5 to 50%, relative to the equivalent weight of the sum of all carboxyl group-containing matrix components.

Transdermal therapeutic system for administering non-steroidal antiphlogistic agents containing carboxyl groups, and a method for the production of the same

This invention provides for a therapeutic system for timed and controlled release of at least one therapeutic active agent to a human or animal organism by diffusion through the skin or mucous membrane. The active agent is initially present, for the purposes of manufacture and storage, in a first state in the form of a pharmaceutically acceptable salt, which is chemically stable and insufficiently permeable for the skin or mucous membrane. The active agent is converted at the application site upon access of moisture and by an activating agent into a second state, which is suitable for diffusion through the skin or mucous membrane and in which it is taken up by the organism. The activating agent is initially present as a solid substance or a mixture or a plurality of such substances, which reacts in aqueous solution as an acid or base. The activating agent contains a portion of water of at least 5% in its solid body structure, either intercalated or bound thereto.

Therapeutic system which can be moisture-activated

A transdermal therapeutic system comprising a largely water vapor-impermeable backing layer, at least one active substance-containing matrix layer comprising the active substance tulobuterol, as well as a removable protective layer, is characterized in that said matrix is built-up on the basis of polyacrylate pressure-sensitive adhesives and contains tulobuterol in the form of its salt tulobuterol hydrochloride as active substance.

Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin

A transdermal therapeutic system having a backing layer, at least one nicotine-containing layer ore zone, which may have pressure-sensitive properties, as well as a removable protective layer is characterized by a content of at least one essential oil extracted from a mint species, or at least one monoterpene ketone contained in these essential oils.

Transdermal therapeutic system with nicotine and addition of monoterpene ketones

A medical pressure sensitive adhesive based on polyacrylates and neutral polyamine salts is characterized in that it has a pressure-sensitive adhesive matrix of two polymer components A and B, with polymer component A being a polyacrylate pressure-sensitive adhesive containing carboxyl groups, the carboxyl groups of which are neutralized; the polymer component B being a neutral polyamine salt obtained by reacting a polyacrylate copolymer containing amino groups with an acid, with the polymer component B being dispersed in the polymer component A, and the two components forming a two-phase system.

Medical contact adhesive comprising a two phase adhesive matrix of polyacrylates and polyamine salts

In a process for the production of polysiloxane pressure-sensitive adhesive layers with reduced cold flow by means of coating and drying a one-component polysiloxane pressure-sensitive adhesive solution onto a suitable flat-shaped carrier, a complex of a metal ion of the group consisting of calcium, magnesium, zinc, aluminum, titanium, zirconium or hafnium with a low-molecular organic complex former is added to the organic adhesive solution to be coated, whereby the metal ion is only released from the bond to the complex former under the conditions of heating and/or drying of the adhesive solution.

Silicone contact adhesive with reduced cold flow

Transdermal therapeutic system with neutralized acrylic adhesive patch

A process for ascertaining the adhesive behaviour of pressure-sensitive adhesive flat materials such as medicinal adhesive tape and, in particular, pressure-sensitive adhesive application systems such as transdermal therapeutic systems (TTS) is characterized in that a flat material (,) with an adhesive layer (,) of a defined coating weight per unit area and of defined quality of the adhesive mass is adhered with predetermined surface pressure and at a predetermined temperature to an elastic carrier film (,) of defined thickness and elasticity, and that said carrier film (,) is clamped into a test cell (,), in the manner of a membrane, between half-shells (,) of a test cell (,), and that the carrier film (,) along with the adhered flat material (,) is subjected, in chronologically repeated sequence, to loading and unloading with alternating elastic stretchings by defined loading forces from the side facing away from the flat material, and that a detachment of the adhesive layer, which detachment arises progressively per unit of time, is observed and qualitatively and/or quantitatively evaluated.

Method and device for determining adhesive performance of flat adhesive products on the skin of humans or mammals

A transdermal therapeutic system (TTS) for the delivery of active compounds to or through the skin, having a layer adhering comparatively permanently to the skin, whose outer edges are defined by a contour, is characterized in that at least two sections which are concave relative to the surface are contained in the contour.

Growing community of inventors

Ochtendung, Germany

Stefan Bracht